HYM Investment Group began construction in March of 2022 on a $280 million biomanufacturing hub in Revere, Mass. Designed by Elkus Manfredi Architects, the six-story life sciences facility will offer leasable research environments for biomedical and pharmaceutical companies. Complemented by retail and dining amenities, the structure will feature two double-height floors for GMP production and manufacturing activities.
Wake Technical Community College opened the $47 million Lilly Science and Technology Center in Morrisville in March of 2022. Designed by O'Brien Atkins Associates, the 66,000-sf facility features smart learning environments for programs in biotechnology and business analytics. Housing a biochemistry lab for training in raw materials testing and in-process sampling, the three-story building also provides a microbiology lab where students can learn best practices for gene therapy, genetics, cell culture, DNA manipulation, and industrial microbiology.
Amgen broke ground in March of 2022 on a $550 million biomanufacturing center in Holly Springs, N.C. Accommodating the company's FleXBatch platform, the project will integrate traditional methods for drug substance production with single-use bioprocessing technologies to create a hybrid facility with unrivaled operational efficiencies. The next-generation plant will manufacture advanced therapeutics for the treatment of cardiovascular disease, cancer, osteoporosis, inflammation, and other conditions.
President Biden on Tuesday signed a federal budget that includes $45 billion for the National Institutes for Health (NIH)—a $2.25 billion, 5.3 percent increase—and provides an additional $1 billion to establish the new Advanced Research Projects Agency for Health (ARPA-H). According to the NIH, “ARPA-H will be tasked with building high-risk, high-reward capabilities (or platforms) to drive biomedical breakthroughs—ranging from molecular to societal—that would provide transformative solutions for all patients.” The $45 billion will be distributed among the institutes and centers, with none receiving less than a 3.4 percent boost.
Piramal Pharma Solutions broke ground in February of 2022 on a £45 million antibody drug conjugate (ADC) facility in Grangemouth, Scotland. Accommodating both manufacturing and aseptic fill/finish operations, the structure will provide additional capacity for the creation of targeted cancer treatments and other innovative therapies. Representing an expansion of Piramal's existing ADC campus, the project is being delivered by Merit using its FlexiPOD V4.0 platform.
Vibalogics completed construction in December of 2021 on a $150 million virotherapy facility in Boxborough, Mass. Sited on 145 acres, the next-generation manufacturing plant supports commercial production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products. The highly flexible structure incorporates 2,000-liter bioreactors, multiple cGMP production suites, offices, warehouse space, and labs for research, development, and quality control.
XNRGY Climate Systems is planning to construct its US headquarters in Maricopa County, Arizona. Designed by Gensler, the $300 million facility will provide one million sf of advanced manufacturing space for the production of next-generation HVAC solutions. Accelerating research and development in key areas such as immersion cooling, the sustainably designed complex will enable XNRGY to meet growing demand in sectors including hyperscale data centers, life sciences, semiconductor cleanrooms, energy storage, and healthcare.
Exact Sciences Corporation will begin construction in spring of 2022 on the Research and Development Center of Excellence in Madison, Wis. Designed by Potter Lawson, the 266,000-sf facility will catalyze further innovations in multi-cancer early detection and enhance the company's flagship product, Cologuard. Completion is expected in 2024.
Pfizer opened a $68.5 million clinical manufacturing facility in December of 2021 in Durham. Accommodating the company's BioTherapeutics Pharmaceutical Sciences division, the 85,500-sf project will support the creation of gene therapies for the treatment of hemophilia A, hemophilia B, Duchenne muscular dystrophy, and other diseases. Leveraging single-use bioreactors to enable scalable expansion over time, the structure provides multiple drug substance suites, analytical and microbiology labs, and areas for manufacturing and filling.
Washington University School of Medicine will break ground in spring of 2022 on a $150 million vertical expansion of the Steven & Susan Lipstein BJC Institute of Health in St. Louis. Designed by Lawrence Group to promote collaboration and discovery, the six-story, 160,000-sf addition will provide 103,000 sf of biomedical research space and a 7,900-sf BSL-3 laboratory for the study of infectious diseases such as SARS-CoV-2 and tuberculosis.
BeiGene is planning to break ground in 2022 on a pharmaceutical manufacturing and research center in Hopewell, N.J. Located on the Princeton West Innovation Campus, the integrated complex will provide 400,000 sf of dedicated space for commercial-stage production of innovative cancer therapies. Offering up to 16,000 liters of biologics capacity, the facility will also include clinical R&D labs and collaborative office environments. IPS is the architect and engineer for the project, which will be built by DPR Construction.
Autolus Therapeutics broke ground in November of 2021 on a £66 million cell manufacturing facility in Stevenage in the United Kingdom. Accommodating the production of chimeric antigen receptor T-cells for the treatment of cancer, the 80,730-sf project is being built by Merit using modular offsite construction methodology to significantly accelerate the construction timeline and reduce carbon emissions.
Amgen broke ground in November of 2021 on a $365 million biomanufacturing plant in New Albany, Ohio. Created by the design-build team of CRB and Turner Construction, the smart factory will leverage advanced automation technologies to optimize the assembly and packaging of injectable medicines. The 270,000-sf facility will accommodate 400 new employees and an array of collaborative and industrial robots.
FUJIFILM Diosynth Biotechnologies broke ground in October of 2021 on a $2 billion production facility in Holly Springs, N.C. Enabling large-scale cell culture manufacturing for the creation of bulk drug substances, the structure will accommodate eight 20,000-liter bioreactors with the expansion potential for a further 24 20,000-liter bioreactors to meet market demand. Powered by clean energy, the sustainably designed complex will feature advanced systems for waste disposal and recycling.
AstraZeneca is planning to construct a $360 million manufacturing center in the Blanchardstown region of Dublin. Located on the Alexion Campus in College Park, the next-generation facility will leverage advanced process technologies and digital innovation solutions to produce small-molecule APIs (active pharmaceutical ingredients). Significantly reducing commercialization lead times, the sustainably designed structure will integrate lean manufacturing practices to lower operating costs and reduce carbon emissions.
